AU2010256013B2 - Glomerulonephritis treatment - Google Patents

Glomerulonephritis treatment Download PDF

Info

Publication number
AU2010256013B2
AU2010256013B2 AU2010256013A AU2010256013A AU2010256013B2 AU 2010256013 B2 AU2010256013 B2 AU 2010256013B2 AU 2010256013 A AU2010256013 A AU 2010256013A AU 2010256013 A AU2010256013 A AU 2010256013A AU 2010256013 B2 AU2010256013 B2 AU 2010256013B2
Authority
AU
Australia
Prior art keywords
compound
formula
group
cox
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010256013A
Other languages
English (en)
Other versions
AU2010256013A1 (en
Inventor
Andrea Huwiler
Berit Johansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coegin Pharma AS
Original Assignee
Avexxin AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avexxin AS filed Critical Avexxin AS
Publication of AU2010256013A1 publication Critical patent/AU2010256013A1/en
Application granted granted Critical
Publication of AU2010256013B2 publication Critical patent/AU2010256013B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2010256013A 2009-06-04 2010-06-04 Glomerulonephritis treatment Ceased AU2010256013B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0909643.9 2009-06-04
GB0909643A GB0909643D0 (en) 2009-06-04 2009-06-04 Glomerulonephritis treatment
PCT/EP2010/003384 WO2010139482A1 (en) 2009-06-04 2010-06-04 Glomerulonephritis treatment

Publications (2)

Publication Number Publication Date
AU2010256013A1 AU2010256013A1 (en) 2012-01-12
AU2010256013B2 true AU2010256013B2 (en) 2013-05-16

Family

ID=40936918

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010256013A Ceased AU2010256013B2 (en) 2009-06-04 2010-06-04 Glomerulonephritis treatment

Country Status (14)

Country Link
US (3) US8796251B2 (enExample)
EP (2) EP2437739B1 (enExample)
JP (1) JP5837481B2 (enExample)
AU (1) AU2010256013B2 (enExample)
CA (1) CA2764465C (enExample)
CY (1) CY1118269T1 (enExample)
DK (2) DK2437739T3 (enExample)
ES (2) ES2546198T3 (enExample)
GB (1) GB0909643D0 (enExample)
HU (2) HUE030085T2 (enExample)
LT (1) LT2745837T (enExample)
PL (2) PL2437739T3 (enExample)
PT (2) PT2745837T (enExample)
WO (1) WO2010139482A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014633D0 (en) 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) * 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201501144D0 (en) 2015-01-23 2015-03-11 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CA3037582A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
JP7305562B2 (ja) * 2017-06-16 2023-07-10 アヴェクシン エーエス 線維性疾患の治療のための組成物および方法
GB201910644D0 (en) 2019-07-25 2019-09-11 Coegin Pharma As Cancer Treatment

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670465A (en) * 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
EP0765661A2 (en) * 1995-09-26 1997-04-02 Shiseido Company Limited Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
WO2002060535A1 (en) * 2001-01-31 2002-08-08 Leff Alan R Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2?
WO2003063878A1 (en) * 2002-01-29 2003-08-07 Leiv Eiriksson Nyskaping As Use of polyunsaturated ketones for the treatment of psoriasis
WO2008075978A2 (en) * 2006-12-20 2008-06-26 Seperex Nutritionals Limited An extract
WO2008075366A2 (en) * 2006-12-20 2008-06-26 Medwell Laboratories Ltd. Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09268153A (ja) 1996-04-02 1997-10-14 Sagami Chem Res Center トリフルオロメチルケトン誘導体及びホスホリパーゼａ２阻害剤
US6262119B1 (en) * 1996-04-12 2001-07-17 Peptide Technology Limited Methods of treating immunopathologies using polyunsaturated fatty acids
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
US6031014A (en) 1998-12-08 2000-02-29 Crivello; James V. Initiator compositions and methods for their synthesis and use
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
CA2516142A1 (en) * 2003-03-18 2004-09-30 Novartis Ag Compositions comprising fatty acids and amino acids
WO2009061208A1 (en) * 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670465A (en) * 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
EP0765661A2 (en) * 1995-09-26 1997-04-02 Shiseido Company Limited Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
WO2002060535A1 (en) * 2001-01-31 2002-08-08 Leff Alan R Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2?
WO2003063878A1 (en) * 2002-01-29 2003-08-07 Leiv Eiriksson Nyskaping As Use of polyunsaturated ketones for the treatment of psoriasis
WO2008075978A2 (en) * 2006-12-20 2008-06-26 Seperex Nutritionals Limited An extract
WO2008075366A2 (en) * 2006-12-20 2008-06-26 Medwell Laboratories Ltd. Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALBRIGHTSON CHRISTINE R ET AL: "Selective inhibition of 5-1ipoxygenase attenuates glomerulonephritis in the rat" KIDNEY INTERNATIONAL,vol. 45, no. 5, 1994, pages 1301-1310, *
CYBULSKY ANDREY VET AL: JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 44, 1 November 2002 (2002-11-01), pages 41342-41351, *
FLOCK S ET AL:SYNTHETIC COMMUNICATIONS, TAYLOR & FRANCIS GROUP, PHILADELPHIA, PA LNKDDOI: ,vol. 37, no. 22,1 January 2007 (2007-01- 01), pages 4005-4015 *
HANSEN T VET AL: TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.TETLET.2004.02.024,vol. 45, no. 13,22 March 2004 (2004-03-22), pages 2809- 2811 *
LARSEN L NET AL: "POLYUNSATURATED THIAAND OXA-FATTY ACIDS: INCORPORATION INTO CELL-LIPIDS AND THEIR EFFECTS ON ARACHIDONIC ACID- AND EICOSANOID SYNTHESIS" BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER,NL,vol. 1348, no. 3, 1997 pages 346-354 *
PAPANIKOLAOU ET AL: PROSTAGLANDINS, LEUKOTRIENES AND MEDICINE, CHURCHILL LIVINGSTONE, EDINBURGH, NEW YORK, GB LNKD001: 10.1016/0262-1746(87)90066-7, vol. 27, no. 2-3, 1 May 1987 *
SHI Y ET AL: JOURNAL OF NUTRITIONAL BIOCHEMISTRY,vol. 17, no. 10,1 October 2006 (2006-10-01), pages 697-706, *

Also Published As

Publication number Publication date
CY1118269T1 (el) 2017-06-28
DK2437739T3 (en) 2015-08-17
PT2745837T (pt) 2016-08-22
US20120136066A1 (en) 2012-05-31
WO2010139482A1 (en) 2010-12-09
LT2745837T (lt) 2016-10-25
AU2010256013A1 (en) 2012-01-12
PL2745837T3 (pl) 2017-01-31
HUE027050T2 (en) 2016-08-29
PT2437739E (pt) 2015-10-12
CA2764465A1 (en) 2010-12-09
PL2437739T3 (pl) 2015-11-30
JP2012528813A (ja) 2012-11-15
ES2587719T3 (es) 2016-10-26
HUE030085T2 (en) 2017-04-28
EP2745837B1 (en) 2016-07-27
US20140256824A1 (en) 2014-09-11
CA2764465C (en) 2018-03-20
EP2437739B1 (en) 2015-07-29
GB0909643D0 (en) 2009-07-22
DK2745837T3 (en) 2016-08-29
EP2745837A1 (en) 2014-06-25
US8796251B2 (en) 2014-08-05
JP5837481B2 (ja) 2015-12-24
US20100311843A1 (en) 2010-12-09
EP2437739A1 (en) 2012-04-11
US9187396B2 (en) 2015-11-17
ES2546198T3 (es) 2015-09-21

Similar Documents

Publication Publication Date Title
CA2764465C (en) Glomerulonephritis treatment
AU2011298340B2 (en) Rheumatoid arthritis treatment using polyunsaturated long chain ketones
JP6689078B2 (ja) 超高純度なテトラヒドロカンナビノール−１１−酸
ZA200007447B (en) Inhibitors of transcription factor NF-kB.
CN102333754B (zh) 洛索洛芬衍生物和含有其的药品
TWI293301B (en) A1 adenosine receptor antagonists
JP2021534249A (ja) ３−アリールオキシ−３−アリール−プロピルアミン化合物およびその用途
AU2013351329A1 (en) Dermatitis treatment
AU2016313138A1 (en) Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
JP5177889B2 (ja) 混合ジスルファニルの形態のジスルファニル基を含有するアミノ酸誘導体とアミノペプチダーゼ阻害剤
HUP0102492A2 (hu) Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
US20050032881A1 (en) Novel non-psychotropic cannabinoids
DE19803003A1 (de) 5-Aroylnaphthalinderivate
Halen et al. Synthesis and Pharmacological Evaluation of Some Dual‐Acting Amino‐alcohol Ester Derivatives of Flurbiprofen and 2‐[1, 1′‐Biphenyl‐4‐yl] acetic Acid: A Potential Approach to Reduce Local Gastrointestinal Toxicity
CN117242076A (zh) 基于噻吩的化合物及其作为bckdk抑制剂的用途
Wang et al. Discovery and optimization of ester-linked ibuprofen-glycine hybrids as the NF-κB pathway inhibitors for the treatment of ulcerative colitis
TWI293880B (en) Use of pdgf receptor tryosine kinase inhibitors for the treatment of diabetic nephropathy
HK40123243A (en) Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors
JP2008543741A (ja) 新規な化合物
CN114315689A (zh) 二硫烷基邻苯二甲酰亚胺类化合物、其制备方法和用途
WO2019159868A1 (ja) 大腸炎改善剤
MXPA00012498A (en) INHIBITORS OF TRANSCRIPTION FACTOR NF-&kgr;B

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired